Aryl iodides
Apexbio Technology LLC 4-iodo-SAHA 1219807-87-0 500mg
4-iodo-SAHA (CAS 1219807-87-0) is a hydrophobic analog of suberoylanilide hydroxamic acid (SAHA) that functions as a histone deacetylase (HDAC) inhibitor targeting both class I and II HDACs By blocking HDAC activity 4-iodo-SAHA modulates the reversible acetylation of lysine residues on histone and non-histone proteins affecting transcriptional regulation In cellular assays 4-iodo-SAHA demonstrated antiproliferative effects with EC50 values of 1 1 M in SKBR3 breast cancer cells and 0 95 0 12 0 24 0 85 and 1 3 M in HT29 U937 JA16 HL60 and K562 tumor cell lines respectively Notably it exhibited greater potency than SAHA in inhibiting proliferation of U937 leukemia cells These properties make 4-iodo-SAHA valuable for investigating HDAC-related cellular processes and cancer models
Medchemexpress LLC Ethoxymethyl benzene | 539-30-0 | MFCD00039903 | 99.0% | 136.19 | C9H12O | 1 ML
(Ethoxymethyl)benzene is an endogenous metabolite used as an analytical reference and reagent for research applications (CAS 539-30-0). It is a colorless to light yellow liquid (C9H12O, 136.19 g/mol) available as a neat liquid, analytical standard, or a 10 mM solution in DMSO for calibration, assay development, and metabolite studies.
- High listed purity (98.99%) suitable for analytical work.
- Available as neat liquid, analytical standard, and ready-to-use solution.
- Suitable for calibration, quantitation, and metabolite research.
- Liquid: colorless to light yellow; density 0.949 g/cm3.
- Storage recommendations provided to maintain stability in pure form and in solvent.
eMolecules ChemScene / 8-Iodoisoquinoline / 100mg / 628860926 / CS-0187286 / 0.000 / 1131605-27-0 / MFCD11865312 / 255.058 / C9H6IN
ChemScene / 8-Iodoisoquinoline / 100mg / 628860926 / CS-0187286 / 0.000 / 1131605-27-0 / MFCD11865312 / 255.058 / C9H6IN
Chemscene ChemScene | 4-Iodo-1H-imidazole | 25G | CS-W002802 | 0.98 | 71759-89-2| MFCD01632213 | 193.97
ChemScene | 4-Iodo-1H-imidazole | 25G | CS-W002802 | 0.98 | 71759-89-2| MFCD01632213 | 193.97
Medchemexpress LLC AG-205 | 00-00-0 | 99.0% | 454.98 | C22H23ClN6OS | 5 MG
AG-205 is a small-molecule inhibitor of progesterone receptor membrane component-1 (PGRMC1) provided for research use. It displays anti-mitotic, anti-migratory, and anti-invasive activity, modulates apoptosis and cell-cycle regulation, and influences expression of genes involved in cholesterol biosynthesis and steroidogenesis.
- PGRMC1 inhibitor activity relevant for cell-signaling studies.
- Anti-mitotic, anti-migratory, and anti-invasive effects in cancer cell models.
- Modulates apoptosis and cell-cycle regulatory pathways.
- Alters expression of genes involved in cholesterol biosynthesis and steroidogenesis.
- High purity (99%) suitable for research applications.
- Stable as a powder under recommended cold storage conditions.
Apexbio Technology LLC Nintedanib (BIBF 1120) 656247-17-5 10mM (in 1mL DMSO)
Nintedanib (BIBF 1120 CAS 656247-17-5) is an orally bioavailable small-molecule tri-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3) fibroblast growth factor receptors (FGFR1-3) and platelet-derived growth factor receptors (PDGFR / ) By inhibiting these receptor pathways at nanomolar concentrations (IC50 20 100 nmol/L) Nintedanib disrupts angiogenesis signaling and demonstrates antiangiogenic activity It is extensively investigated in preclinical and clinical research for idiopathic pulmonary fibrosis (IPF) as well as oncology including non-small-cell lung carcinoma ovarian cancer colorectal cancer and hepatocellular carcinoma
eMolecules Pharmablock tert-butyl 6-iodo-2-azaspiro[3 3]heptane-2-carboxylate 500mg 713714201 PBXH381 0 000 2059140-61-1 323 174 C11H18INO2
Pharmablock tert-butyl 6-iodo-2-azaspiro[3 3]heptane-2-carboxylate 500mg 713714201 PBXH381 0 000 2059140-61-1 323 174 C11H18INO2
Medchemexpress LLC MyoMed 205 | 2614161-13-4 | 98.0% | 491.56 g/mol | C26H25N3O5S | 10 MG
MyoMed 205 is a small-molecule inhibitor of MuRF1 supplied as a white to off-white solid for research use. It reduces ubiquitination and proteasomal degradation of muscle proteins and has been used in preclinical studies to prevent early diaphragmatic systolic dysfunction and muscle atrophy. Recommended handling includes storage of the powder at low temperature and preparation of solutions in DMSO with warming as needed.
- Small-molecule MuRF1 inhibitor for research use.
- White to off-white solid with high reported purity.
- Soluble in DMSO at up to 25 mg/mL with sonication and warming.
- Formulatable for in vivo dosing in 10% DMSO/90% corn oil at ≥ 2.5 mg/mL.
- Store powder at -20°C for long-term stability.